// Paulina Ćwiek 1 , Zaira Leni 1 , Fabiana Salm 1 , Valeriya Dimitrova 1 , Beata Styp-Rekowska 2 , Gianpaolo Chiriano 3 , Michael Carroll 4 , Katrin Höland 1 , Valentin Djonov 2 , Leonardo Scapozza 3 , Patrick Guiry 4 and Alexandre Arcaro 1 1 Division of Pediatric Hematology/Oncology, Bern University Hospital, Bern, Switzerland 2 Institute of Anatomy, University of Bern, Bern, Switzerland 3 Pharmaceutical Biochemistry, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland 4 Centre for Synthesis and Chemical Biology, University College Dublin, Belfield, Dublin, Ireland Correspondence: Alexandre Arcaro, email: // Keywords : c-Myc, medulloblastoma, PCTK1, RNA interference, synthetic lethality Received : August 19, 2014 Accepted : November 06, 2014 Published : November 06, 2014 Abstract Medulloblastoma (MB) is the most common malignant brain tumor in children and is associated with a poor outcome. cMYC amplification characterizes a subgroup of MB with very poor prognosis. However, there exist so far no targeted therapies for the subgroup of MB with cMYC amplification. Here we used kinome-wide RNA interference screening to identify novel kinases that may be targeted to inhibit the proliferation of c-Myc-overexpressing MB. The RNAi screen identified a set of 5 genes that could be targeted to selectively impair the proliferation of c-Myc-overexpressing MB cell lines: AKAP12 ( A-kinase anchor protein), CSNK1α1 (casein kinase 1, alpha 1), EPHA7 (EPH receptor A7) and PCTK1 (PCTAIRE protein kinase 1). When using RNAi and a pharmacological inhibitor selective for PCTK1, we could show that this kinase plays a crucial role in the proliferation of MB cell lines and the activation of the mammalian target of rapamycin (mTOR) pathway. In addition, pharmacological PCTK1 inhibition reduced the expression levels of c-Myc. Finally, targeting PCTK1 selectively impaired the tumor growth of c-Myc-overexpressing MB cells in vivo . Together our data uncover a novel and crucial role for PCTK1 in the proliferation and survival of MB characterized by cMYC amplification.
No takes yet. Share an insight, caveat, or question.
Ćwiek et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: